Plain-English translation of NCT07484217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called solriamfetol to see if it can help people who have depression and also experience excessive daytime sleepiness—that overwhelming tiredness during the day that makes it hard to function. The study will first give everyone the medication to see who responds well, and then randomly assign those who improve to either keep taking it or switch to a placebo (a pill with no active ingredient) to see if the medication really is what's helping.
Many people with depression also struggle with exhaustion and daytime sleepiness, which can make their depression worse and harder to treat. This medication hasn't been specifically tested for this combination before, so researchers want to understand whether this treatment could help people manage both problems together.
You likely qualify if…
You likely don't qualify if…
You will start by taking the medication for a period of time while researchers monitor how you're doing. If you improve, you'll enter the second phase where you're randomly assigned to either continue the medication or switch to a placebo for the rest of the study—neither you nor the researchers will know which you're taking. Throughout the study, you'll have regular visits to check on your mood, sleepiness, and overall health.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States